Atefe Ataei, Majid Azizi, Samira Hajisadeghi, Mojan Madani, Mozhgan Khorami, Sahar Hassantash, Sahand Saeidpour Masouleh and Ghasem Barati* Pages 1 - 13 ( 13 )
Oral cancers are prevalent in the human population, particularly in unindustrialized countries. In 90 % of oral cancers, the tumors arise from squamous cells, which is called oral squamous cell carcinoma (OSCC). Despite new treatment strategies, the morbidity and mortality rates are still high. Current treatment options including surgery, chemotherapy, and radiotherapy are not effective in the treatment of the tumor. Cell therapy with mesenchymal stem cells (MSCs) is considered one of the leading strategies in cancer treatment. However, the field of MSC therapy in OSCC is immature and ongoing studies are being conducted in experimental and pre-clinical studies. Here, we reviewed these studies to figure out whether the use of MSCs could be worthwhile in OSCC therapy or not. Both native and engineered MSCs as well as their secretome have been used in the treatment of OSCC. It seems that genetically modified MSCs or their secretome could inhibit the tumorigenesis of OSCC. However, further pre-clinical studies are required to come to a conclusion.
Mesenchymal stem cells, Stem cell secretome, Extracellular vesicles, Oral squamous cell carcinoma, Genetically modified stem cells, Drug loading